A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A
Kazuhiro Usui(Hokkaido University Hospital), Kunihiko Kobayashi(Saitama Medical University), Koichi Hagiwara(Jichi Medical University), Ichiro Kinoshita(Hokkaido University), Akira Inoue(Tohoku University Hospital), Hiroshi Sakai(Hiroshima University), Hiroshi Watanabe(Tohoku University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Atsuto Mouri(Saitama Medical University), Shunichi Sugawara(Sendai Kousei Hospital), Masaru Nishitsuji(Ishikawa Prefectural Central Hospital), Yuka Fujita, Yoshihito Ohhara(NTT Medical Center), Hiroshi Kagamu(Saitama International Medical Center)
Cited by 48
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879